Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Nippon Shinyaku said on December 22 that the US FDA has approved the pulmonary arterial hypertension (PAH) treatment selexipag, discovered by the company and licensed to the Swiss drug maker Actelion, with its launch scheduled for early January.The drug, which…
To read the full story
Related Article
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
BUSINESS
- Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
- Alfresa, Partners Seal Share Deal to Formalize Biosimilar JV
November 10, 2026
- Japan Ethical Drug Sales Rise 3.5% in September: Crecon
November 10, 2026
- Shionogi Grabs Japan Nod for Updated COVID Vaccine
November 10, 2026
- Kyorin Nabs Japan Rights to Edesa’s ARDS Drug
November 10, 2026





